Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTime Appoints Co-CEO

This article was originally published in Scrip

Executive Summary

BioTime, Inc., a company focusing on pluripotent stem cell technology, has appointed Adi Mohanty Co-CEO to serve with Michael D. West. Since 2014, Mohanty has been BioTime's chief operating officer and will now lead the company's advanced clinical development programs and commercialization strategies. Before BioTime, Mohanty was at Shire Plc. for 11 years where he most recently was president, head of the regenerative medicine business and previously he was also head of Shire's global franchise portfolio of biologic products for rare diseases. Prior to this, Mohanty held various management positions at Transkaryotic Therapies, Inc. (acquired by Shire) and general management, engineering and manufacturing positions at Baxter Bioscience (now Baxalta).

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC030094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel